Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Understanding the Phase and Morphological Behavior of Dispersions of Synergistic Dual-Stimuli-Responsive Poly(N-isopropylacrylamide) Nanogels.

Town A, Niezabitowska E, Kavanagh J, Barrow M, Kearns VR, García-Tuñón E, McDonald TO.

J Phys Chem B. 2019 Jul 25;123(29):6303-6313. doi: 10.1021/acs.jpcb.9b04051. Epub 2019 Jul 11.

PMID:
31251624
2.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL.

Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006.

PMID:
31085175
3.

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.

Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC.

Oncogene. 2019 Feb;38(8):1200-1210. doi: 10.1038/s41388-018-0508-5. Epub 2018 Sep 21.

4.

Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance.

Bannon AE, Kent J, Forquer I, Town A, Klug LR, McCann K, Beadling C, Harismendy O, Sicklick JK, Corless C, Shinde U, Heinrich MC.

Clin Cancer Res. 2017 Nov 1;23(21):6733-6743. doi: 10.1158/1078-0432.CCR-17-1397. Epub 2017 Jul 19.

5.

Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs.

Town AR, Giardiello M, Gurjar R, Siccardi M, Briggs ME, Akhtar R, McDonald TO.

Nanoscale. 2017 May 18;9(19):6302-6314. doi: 10.1039/c6nr07858c.

PMID:
28368063
6.

Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.

Macleod AC, Klug LR, Patterson J, Griffith DJ, Beadling C, Town A, Heinrich MC.

Mol Cancer Ther. 2014 Dec;13(12):2840-51. doi: 10.1158/1535-7163.MCT-13-0830. Epub 2014 Sep 24.

7.

KIT gene mutations and copy number in melanoma subtypes.

Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL.

Clin Cancer Res. 2008 Nov 1;14(21):6821-8. doi: 10.1158/1078-0432.CCR-08-0575.

8.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.

J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.

9.

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG; Imatinib Target Exploration Consortium Study B2225.

Clin Cancer Res. 2008 May 1;14(9):2717-25. doi: 10.1158/1078-0432.CCR-07-4575.

10.

FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).

Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, Cherrington JM, Heinrich MC.

Leukemia. 2006 Nov;20(11):2008-14. Epub 2006 Sep 14.

PMID:
16990784
11.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC.

J Clin Oncol. 2005 Aug 10;23(23):5357-64. Epub 2005 May 31. Review.

PMID:
15928335
12.

KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.

Corless CL, McGreevey L, Town A, Schroeder A, Bainbridge T, Harrell P, Fletcher JA, Heinrich MC.

J Mol Diagn. 2004 Nov;6(4):366-70.

13.

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC.

Blood. 2004 Dec 15;104(13):4202-9. Epub 2004 Aug 10.

PMID:
15304385
14.

KIT mutations are common in testicular seminomas.

Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC.

Am J Pathol. 2004 Jan;164(1):305-13.

15.

Absence of BRAF and NRAS mutations in uveal melanoma.

Cruz F 3rd, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL.

Cancer Res. 2003 Sep 15;63(18):5761-6.

16.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.

Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16.

PMID:
12531805
17.

PDGFRA activating mutations in gastrointestinal stromal tumors.

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA.

Science. 2003 Jan 31;299(5607):708-10. Epub 2003 Jan 9.

18.

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

Corless CL, McGreevey L, Haley A, Town A, Heinrich MC.

Am J Pathol. 2002 May;160(5):1567-72.

19.

Cataracts in alloxan-diabetic rabbits.

NAIDOFF D, PINCUS IJ, TOWN AE, SCOTT ME.

Am J Ophthalmol. 1955 Apr;39(4 Pt 1):510-7. No abstract available.

PMID:
14361577
20.

Differential diagnosis between solid and serous detachment of the retina.

TOWN AE.

Pa Med J. 1953 Dec;56(12):1046-8. No abstract available.

PMID:
13111860
21.

Cataracts in alloxan diabetic rabbits.

NAIDOFF D, PINCUS IJ, TOWN AE, SCOTT ME.

AMA Arch Ophthalmol. 1953 Aug;50(2):257-60. No abstract available.

PMID:
13064904
22.

Radioactive phosphorus studies in the diagnosis of ocular tumors; a preliminary report.

TOWN AE.

W V Med J. 1952 Dec;48(12):356-9. No abstract available.

PMID:
13006119
23.

Ophthalmic use of terramycin.

TOWN AE.

Am J Ophthalmol. 1951 May;34(5 1):723-6. No abstract available.

PMID:
14829487
24.

Relationship of the endocrines to cataract.

TOWN AE, RAKOFF AE.

Trans Am Ophthalmol Soc. 1950:313-30. No abstract available.

PMID:
14835747
25.

Medical treatment of cataract.

TOWN AE, RAKOFF AE.

Pa Med J. 1951 Jan;54(1):35-8. No abstract available.

PMID:
14807669
26.

Fibrin closure in eye surgery.

TOWN AE.

Am J Ophthalmol. 1950 Sep;33(9):1449-52. No abstract available.

PMID:
14771229
27.

Fibrin closure in surgery of the eye.

TOWN AE.

J Int Coll Surg. 1950 Jul;14(1):114-8. No abstract available.

PMID:
15428696
28.

Fibrin closure in eye surgery.

TOWN AE, NAIDOFF D.

Am J Ophthalmol. 1950 Jun;33(6):879-82. No abstract available.

PMID:
15419241
29.

Relationship of the Endocrines to Cataract.

Town AE.

Trans Am Ophthalmol Soc. 1950;48:313-30. No abstract available.

30.

The use of fibrin coagulum fixation in ocular surgery; in intraocular surgery.

TOWN AE.

Trans Am Acad Ophthalmol Otolaryngol. 1949 Nov-Dec;54:131-3. No abstract available.

PMID:
15396400
31.

The control of experimental anterior-chamber infections with systemic penicillin therapy.

TOWN AE, FRISBEE FC, WISDA JG.

Am J Ophthalmol. 1946 Mar;29:341-5. No abstract available.

PMID:
21018042
32.

Concentration of penicillin in the aqueous humor following systemic administration.

TOWN AE, HUNT ME.

Am J Ophthalmol. 1946 Feb;29:171-75. No abstract available.

PMID:
21015191
33.

Supplemental Content

Support Center